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The ParagraPh To The lefT is taken from the Reviewer’s 
Orientation Manual, the guide NCI reviewers such as 
myself use to evaluate the accomplishments of cancer 
centers seeking NCI-designation. A common shorter 
translation of it is, “the whole is greater than the sum of 
the parts.” For a new cancer center like ours, with high 
aspirations to become an NCI-designated cancer center 
within a decade, “re:align” better reflects what we have 
been doing since my arrival at George Washington 
University (GW) a little more than two years ago.
Together with the senior leaders of the GW School 
of Medicine and Health Sciences (SMHS) and its clinical 
partners, the GW Medical Faculty Associates (MFA), 
GW Hospital, and the Milken Institute School of Public 
Health at GW, we are breaking down old silos and aligning all cancer-related initiatives 
(laboratory, clinical, and population research) into one cohesive entity: the GW Cancer 
Center. This decision to invest significant time and capital in the fight against cancer is 
critically important for Washington, D.C., a community that continues to rank among the 
nation’s leaders in the incidence of and mortality from numerous cancer types.
The GW Cancer Center team has worked diligently to align existing cancer programs 
and many talented faculty members and administrators from GW’s Foggy Bottom campus, 
as well as from our affiliated institution, Children’s National Health System, and paired them 
with strategic new recruits in an effort to create an innovative cancer center in the city and 
the surrounding metropolitan region. So far, we have recruited more than 20 faculty mem-
bers from prestigious academic institutions nationwide to join the GW Cancer Center.
Our alignment and growth has to be strategic; as such, we are building upon our exist-
ing clinical and scientific strengths, and we are tailoring them to fill gaps in cancer care and 
research in the region. We have identified four basic science programs — cancer biology 
(genetics and epigenetics), cancer immunology and immunotherapy, microbial oncology, 
and cancer engineering — and one population sciences program (cancer prevention and 
policy) that have the greatest relevance and impact to our community, and we are investing 
significant effort and resources to make them hallmarks of the GW Cancer Center portfo-
lio. We are also bolstering clinical programs that empower our patients from diagnosis to 
treatment and, ultimately, to survivorship. To achieve these goals, we are looking outside 
our campus boundaries for guidance, and therefore we have selected an external advisory 
board composed of NCI-designated cancer center directors and leaders in the specialties 
where we want to achieve national prominence. Internally, we have established a gover-
nance committee, which includes the dean of SMHS, the CEO of GW Hospital, and the pres-
ident and CEO of the MFA that helped us in making this alignment smooth and effective.  
In the pages of this edition, titled re:align, you can read about our plans to earn an 
NCI designation; our emphasis on lymphoma research and treatment through the use 
of cutting-edge immunotherapeutic approaches, such as CAR T-cell therapy; our efforts 
to address access-to-care issues and other health policy concerns; and our programs to 
improve quality of life for our cancer patients in active treatment and beyond.
On a personal note, the vision we outlined in our first edition, re:imagine, is becoming 
a reality, and this edition, re:align, is a proof that with your support and commitment, we 
can make “the whole greater than the sum of the parts” at GW Cancer Center.  
 “ … The purpose 
of National 
Cancer Institute 
(NCI)‑Designated 
Cancer Centers 
is to capitalize on 
all institutional 
cancer research 
capabilities, integrating 
meritorious programs 
in laboratory, clinical, 
and population 
research into a single 
transdisciplinary 
research enterprise 
across all institutional 
boundaries … .” 
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GW’s pet therapy program 
was started in 2016 by Ja-
mie Glidewell, a former so-
cial work intern at the GW Medi-
cal Faculty Associates. James 
the Poodle (above) is one of the 
therapy dogs who visits patients 
at the GW Cancer Center. 
A POODLE AMONG PATIENTSALIGNING ON LYMPHOMA CARE A CONFLUENCE OF SCIENCE
22Kieron Dunleavy, MD, is the inaugural leader of 
the GW Cancer Center’s 
lymphoma team. The team will 
bring experts together from 
different specialties to grow and 
advance GW’s lymphoma care 
and research offerings. 
6 Microbial oncology is the study of how microbes, 
such as viruses, bacteria, 
or parasites, can be manipulated 
to fight cancer. Some microbes 
can be modified to produce bio-
logical agents to potentially fight 
the disease.
14
GW CANCER CENTER incorporates all of the existing cancer-related activities at the George Washington University (GW), GW School of Medicine and Health Sciences, the GW Medical Faculty 
Associates, the GW Hospital, and Milken Institute School of Public Health at GW, and serves as a platform to refocus and re-energize the university’s efforts in cancer research and patient care. 
For more information about GW Cancer Center visit gwcancercenter.com
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GW Cancer Center 
Receives Avon Grant
IN BRIEF
RAJA MAZUMDER, PhD, ASSOCIATE 
PROFESSOR of biochemistry and 
molecular medicine at the George 
Washington University (GW) School 
of Medicine and Health Sciences, re-
cently received a $1.2 million grant 
from the National Cancer Institute of 
the National Institutes of Health in sup-
port of a three-year project, titled “In-
tegration of Comprehensive Cancer 
Mutation and Expression-Associated 
Data for Biomarker Evaluation and 
Discovery,” to collect and standardize 
the wide array of cancer research data 
available in the scientific community. 
“There is a lot of data already gen-
erated, and that data is growing expo-
nentially,” said Mazumder. “Projects 
like this one will make utilizing that 
data much easier for researchers.”
Mazumder and his research team 
are developing two databases, 
BioMuta and BioXpress. The team 
will pull the data into a framework, 
standardize cancer terms to ensure 
that they are mapped correctly, and 
provide interfaces and applications 
that allow users to easily access  
the data. 
“This project will allow for con-
necting cancer genomics muta-
tion and expression data within an 
evolutionary context,” said Mazum-
der. “The primary outcome will be 
that users of BioMuta and BioXpress 
will be able to identify high priority 
experimental targets for biomarker 
discovery for diagnostics, therapeu-
tics, and prognostics.”
GW Researcher Receives $1.2 Million Grant  
to Standardize Cancer Genomics Data
The george WashingTon Univer-
siTy (gW) Cancer Center received 
a $100,000 check from the Avon 
Foundation for Women at the 15th 
Annual Avon 39 The Walk to End 
Breast Cancer in May. Accepting the 
check on behalf of the GW Cancer 
Center was Mandi Pratt-Chapman, 
MA, associate center director for 
patient-centered initiatives and 
health equity. 
The money will be used to fund 
a patient navigator who will break 
down barriers and provide resources 
to help 300 breast cancer patients 
in the D.C. area. The program will 
also include a new Spanish-speaking 
support group for women living with 
breast cancer.
“Avon’s continued support of our 
patient navigators provides help for 
so many women in the area,” said 
Pratt-Chapman. “Patient navigators 
are crucial resources for women, es-
pecially in a fragmented health care 
system, as they begin and continue 
their fight against breast cancer.”
In July, the GeorGe 
WashInGton Univer-
sity (GW) Cancer Center 
teamed with the ArmorUp 
Campaign for an event 
at the Katzen Cancer 
Research Center infusion 
center. Patients received 
workout gear and en-
couragement to take on 
cancer through physical 
fitness before, during, and 
after cancer treatments.
Armored  
for Life
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IN BRIEF
for eighT consecUTive years The George Washington University Can-
cer Center has partnered with the Marine Corps Marathon (MCM). GW 
Cancer Center hosted a team of marathon and 10k runners for the 42nd 
Annual race through Washington, D.C., and Arlington, Virginia, Oct. 22.
Money raised through this charitable partnership goes to help cancer 
patients across the D.C.-metropolitan area, and supports the GW Cancer 
Center’s mission to drive innovative research, personalized care, and 
cancer policy in the nation’s capital. 
For more information about the GW Cancer Center MCM teams,  
email gwcimcm@gwu.edu.
Pounding the Pavement  
for Cancer Patients
researchers aT The george WashingTon University 
(GW) exploring the genomic data from women 
with a genetic risk for breast cancer, who may 
never develop cancer, found their cancer-
free state may be related to a second ge-
netic variation. Looking at data of women 
with BRCA 1/2 genetic mutations, GW 
scientists discovered that some women 
also had a co-occurrence of a rare COMT 
genetic variant.
“Not all mutation carriers develop the 
disease, and the underlying reasons for this 
should be looked at, particularly with the large 
data sets now available to researchers,” said An-
elia Horvath, PhD, senior author for the study and as-
sociate research professor of pharmacology and physiology 
at the GW School of Medicine and Health Sciences.
The study, titled “Co-Occurrence of COMT and 
BRCA 1/2 Variants in a Population” and pub-
lished in the New England Journal of Medi-
cine, outlines a strategy for exploring simi-
lar genetic mutations.
“We do not claim the variant is pre-
ventative of breast cancer in BRCA 1/2 
carriers; further research is needed to 
make those claims,” said Horvath. “What 
we have done is illustrate a strategy for 
looking at the many data sets available for 
scientists today to look at different genes, 
different mutations, and discover patterns for 
why someone may never develop the disease pre-
disposed by their high-risk mutation.”
Study Finds Genetic Variations May Offer  
a Strategy for Reducing Breast Cancer Incidence
The american associaTion for 
The Advancement of Science (AAAS) 
named Patricia Berg, PhD, profes-
sor of biochemistry and molecular 
medicine at the George Washington 
University School of Medicine and 
Health Sciences, a fellow of the AAAS. 
Berg was selected for her “impor-
tant contributions to cancer research 
with the discovery of BP1 protein, 
activated in 80 percent of breast 
cancers and 70 percent of prostate 
cancers,” according to the AAAS.
Berg also discovered that the 
presence of BP1 protein increases as 
breast cancer progresses from nor-
mal tissue to aggressive breast can-
cer. BP1 is associated with increased 
cell growth, resistance to drugs, and 
metastasis. Moreover, BP1 protein 
can control other genes, including 
several oncogenes known to cause 
breast cancer. Her work has had a 
dramatic effect on cancer research.
Patricia Berg 
Selected  
as AAAS Fellow 
GW Researcher Receives $1.2 Million Grant  
to Standardize Cancer Genomics Data
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FOR EDWARD SETO, PhD, ASSOCIATE 
center director for basic sciences at 
the George Washington University 
(GW) Cancer Center and professor 
of biochemistry and molecular medi-
cine at the GW School of Medicine 
and Health Sciences, the key to a long 
career in cancer research is simple: 
“Rather than try to know everything, 
we should focus on how we can con-
tribute a small piece to a large puz-
zle.”
Seto’s small pieces — in the form 
of cancer epigenetics and histone 
deacetylase enzymes, or HDACs — 
have helped him chip away at finding 
a cure. Basic epigenetics boils down 
to “good” and “bad” genes in cells; 
the bad appear in cancer cells, the 
good in normal cells. HDACs can af-
fect gene expression without altering 
DNA, and Seto, by regulating gene 
expression, is working to turn off the 
bad genes and bring cancer cells 
back to normal cells.
“I’m honored today to be given 
this opportunity to contribute … to 
the GW Cancer Center, the medical 
school, the university, and the educa-
tional ambitions and goals of the late 
King Fahd,” said Seto at his instal-
lation as the King Fahd Professor of 
Cancer Biology on Feb. 6. 
King Fahd bin Abdulaziz Al Saud, 
who ruled Saudi Arabia from 1982 
until his death in 2005, was “some-
body who cared very much about 
education,” according to his nephew, 
Abdullah Al-Saud, ambassador to the 
United States at the Royal Embassy 
of Saudi Arabia. King Fahd served as 
minister of education from 1954 to 
1960, and he helped lay the founda-
tion for a nationwide school system.
“I’m very happy to be part of 
the celebration of something that 
somebody I knew was behind,” said 
Al-Saud, after accepting a framed 
medallion commemorating the 
installation. 
Saudi Arabia and GW, under King 
Fahd’s leadership, began combin-
ing efforts in education in the 1990s, 
and the relationship has continued to 
grow, culminating in the installation.
With that support, Seto is pre-
pared to follow another life lesson: 
“As a scientist, you must follow your 
results and data, trust your instincts, 
stay on your path, but be prepared 
for unexpected turns. Keep going 
until you find it, and don’t let anyone 
discourage you.”
Edward Seto, PhD, Installed as  
King Fahd Professor of Cancer Biology
IN BRIEF
INSTALLATION HIGHLIGHTS LONG-STANDING RELATIONSHIP BETWEEN SAUDI ARABIA AND GW
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in 1995, local nonProfiT organi-
zaTion the Prevent Cancer Founda-
tion conducted a needs assessment 
of the Washington, D.C., community 
and determined that women in the 
region, particularly in medically un-
derserved neighborhoods, were not 
getting screened for breast cancer. 
The city, they determined, had many 
gaps in access to mammography ser-
vices, and a mobile mammography 
program, such as a “mammovan,” 
might help close those gaps.
“The barriers to screening, par-
ticularly in terms of transportation, 
prevented women from getting to 
a mammography facility,” recalls 
Carolyn “Bo” Aldigé, president and 
founder of the Prevent Cancer Foun-
dation. Insurance and cost, she adds, 
are other key problems. “We wanted 
to start a program where women 
could get screened, free-of-charge.”
The foundation put the call out 
for partners and, after evaluating all 
of the proposals, chose the George 
Washington University (GW). “To-
gether, we founded The GW Medical 
Faculty Associates Mobile Mam-
mography Program, and we’ve been 
partners in it ever since,” she says.
From that initial partnership has 
grown a relationship of more than 20 
years, and in that time, the Alexandria, 
Virginia-based nonprofit has provided 
more than $4 million in support for 
the university’s cancer programs.
“Our mission,” explains Aldigé, “is 
saving lives through cancer preven-
tion and early detection. It’s very 
important to fund research, support 
education, and provide community 
outreach, which to us means meeting 
the needs of the medically under-
served — the uninsured and underin-
sured. Sometimes that means taking 
your programs to where the people 
in need are in the community.”
Each year since that initial grant 
to create the GW Mammovan, the 
Prevent Cancer Foundation has 
awarded grants to GW to support 
the program and keep it rolling to 
communities in need of screening. In 
2005, the Prevent Cancer Foundation 
provided another large grant to fund 
the purchase of a replacement van. 
That support has increased access to 
mammography services throughout 
Washington, D.C., providing care to 
more than 2,000 women annually.
“We are very proud of this 20-year 
association. We feel the need is still 
there, and this has grown into a pro-
gram that women in the community 
really trust and rely on. It’s been a 
great partnership,” says Aldigé. “We 
have always felt that GW plays an 
important role in the community.”
On the Road to  
Cancer Prevention
IN BRIEF
an inTernaTional sUrvey on 
sUn exposure behaviors and 
skin cancer detection found 
there are many imperfections 
and geographic inequalities in 
prevention of skin cancer. 
Information from the study, 
published in the Journal of the 
European Academy of Dermatol-
ogy & Venereology by research-
ers from La Roche-Posay and the 
George Washington University 
(GW) Department of Dermatol-
ogy, could help inform future 
awareness campaigns developed 
to address the need to reduce 
the incidence of skin cancer. 
With nearly 20,000 partici-
pants around the world, it was 
one of the largest international 
studies of its kind on consumer 
sun protection and behaviors. 
Survey results indicated that 88 
percent of respondents were 
aware of the risks of developing 
skin cancer when exposed to the 
sun without protection. However, 
four in 10 respondents said they 
don’t think to protect themselves 
from the sun outside of vacation.
“This is a global wake-up call,” 
says Adam Friedman, MD, senior 
author for the study and associ-
ate professor of dermatology at 
the GW School of Medicine and 
Health Sciences. “There are still 
a lot of gaps in people not only 
actively monitoring for cancer, 
but also preventing it.”
According to the data, using 
sunscreen and wearing sunglass-
es were the most frequent preven-
tive measures. Education level, as 
well as gender, influenced the de-
gree of sun protection: A higher 
level of education corresponded 
to a higher level of sun protection.
The Skinny on  
Sun Exposure
Each year since the initial 
grant to create the GW 
Mammovan, the Prevent 
Cancer Foundation has 
awarded grants to GW to 
support the program.
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“iT’s an oPPorTUne Time To build something new in lymphoma,” says Kieron Dunleavy, 
MD, inaugural leader of the George Washington University (GW) Cancer Center’s lym-
phoma team. The GW Cancer Center is doing just that — bringing experts together from 
different specialties to create world-class lymphoma care offerings. 
Dunleavy will draw upon support from GW Cancer Center Director Eduardo Soto-
mayor, MD, and Mitchell Smith, MD, PhD, associate center director for clinical investiga-
tions at the GW Cancer Center, to grow and advance GW’s lymphoma care and research 
offerings.
One major component is a synergy between 
the GW Cancer Center and Children’s National 
Health System (Children’s National), which is 
opening the door to cutting-edge treatments.
Researchers at Children’s National pioneered 
novel cell-based cancer therapies for patients 
with Epstein-Barr virus (EBV)-associated lym-
phomas, as well as more recently for patients 
with Hodgkin’s disease and non-Hodgkin’s lym-
phoma that are not EBV associated, says Cath-
erine Bollard, MD, director of the Program for 
Cell Enhancement and Technologies for Immu-
notherapy at Children’s National and professor 
of pediatrics and of microbiology, immunology, 
and tropical medicine at the GW School of Med-
icine and Health Sciences (SMHS).
Children’s National currently treats lympho-
ma patients with CAR T-cells, immune system 
cells that are genetically engineered to kill can-
cer. Even adult lymphoma patients seek care at 
Children’s National, Bollard says. However, the 
new collaboration will allow adult patients to re-
ceive care at the GW Cancer Center through an 
extension of the Children’s National cell therapy program, she notes.
“It’s an incredibly exciting time for the field of immunotherapy,” Bollard says. “To be 
able to extend more into the adult cancer space is very exciting. I think with the unique 
talent at GW [Cancer Center], this synergizes extremely well with … where we should be 
going in the lymphoma field.”
“I want to 
understand what 
the needs are in 
D.C. and really 
address those 
in a unique way 
that has not been 
done before.”
KIERON DUNLEAVY, MD
Aligning on 
Lymphoma Care
BRINGING EXPERTS TOGETHER 
FOR WORLD-CLASS CARE 
Kieron Dunleavy, MD (right), is the inau-
gural leader of the GW University Cancer 
Center’s lymphoma team. The team will 
bring experts together from different 
specialties to grow and advance GW’s 
lymphoma care and research offerings. 
BY KATHERINE DVORAK
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That expertise will help the GW Cancer Center attract patients and new clinical tri-
als, adds Smith. “We will have things here that nobody else has because of the partner-
ship with Children’s [National],” he says. “They’re really a world-class program in cellular 
immunotherapy.”
In addition to the expertise from Children’s National, Dunleavy brings his own prowess 
in lymphoma research to GW after years of working in the field at the National Cancer 
Institute. Dunleavy says his major research interest is in diffuse large B-cell lymphoma, an 
aggressive form of lymphoma that can arise in lymph nodes, the gastrointestinal tract, the 
skin, the brain, or bone, among other locations. As the lymphoma offerings build up, he 
says he’ll continue his research here.
Another key focus, Dunleavy adds, will be lymphomas that mainly impact people in 
their teens and 20s. Areas of research will include Burkitt lymphoma, in which cancer 
starts in immune cells called B-cells, and mediastinal large B-cell lymphoma.
These patients’ lymphomas “are unique. If you look at their molecular biology, it’s dif-
ferent from that of children and adults,” Dunleavy says. “This suggests that there is a need 
to study AYA [adolescent and young adult] lymphoma in specific clinical trials.”
Dunleavy says the GW Cancer Center and Chil-
dren’s National will be able to work together to bet-
ter serve that group, especially by building local 
studies geared toward that patient population.
The clinical partner institutions could create a 
model for the rest of the country as young lympho-
ma patients shift to adult care, Dunleavy points out. 
“I think GW and Children’s National is a great plat-
form to have this transition go well, to have the adult 
lymphoma doctors talk with the children lymphoma 
doctors, and to embark on new research.” 
Dunleavy says that paying attention to lymphoma 
issues in Washington, D.C., will be top of mind for 
his team. 
“GW is a fantastic place because it has such a 
strong public health school [the Milken Institute 
School of Public Health] and a strong infectious dis-
ease program,” Dunleavy says. “I want to understand 
what the needs are in D.C. and really address those 
in a unique way that has not been done before.”
Another component is the Cutaneous Lympho-
ma Multidisciplinary Clinic, established by Frank 
Glass, MD, professor of dermatology and pathology 
at SMHS.
The clinic aligns a variety of specialties for the care of patients with these disorders, 
Glass says. “You need a lot of resources to take care of these patients. So we’ll have der-
matology, hematology/oncology, hematopathology, and radiation … because the dis-
ease has many different clinical presentations,” he explains.
Glass notes that the clinic will offer patients “virtually every level of diagnostics and 
treatment modalities.” These will include skin-directed creams, chemotherapy, photo-
therapy, light therapy, and radiation.
In addition to the larger treatment offering, Glass says the clinic will work to reach out 
to patients in the community to sign them up for clinical trials.
That community outreach will extend to physicians in and around Washington, D.C. 
as well. “We’ll interface with community physicians, not only so they can recommend pa-
tients for clinical trials, but also to help with follow-up and continuity of care,” Glass says. 
“Our skills and training are particularly conducive for the interdisciplinary approach,” 
he adds. “A lot of places are missing the key components of the team that make this sys-
tem work, but we have that.”
Lymphoma 
Facts >>
 > There are two forms of 
lymphoma: Hodgkin’s 
lymphoma and non-Hodg-
kin’s lymphoma. With 
Hodgkin’s lymphoma, 
cancer cells make up just 
a small number of the 
cells in a cancerous lymph 
node, while the rest of the 
cells are normal immune 
cells. In non-Hodgkin’s 
lymphoma, cancer cells 
make up most of a tumor. 
Hodgkin’s and non-Hodg-
kin’s lymphoma also differ 
in the way they spread and 
in how they are treated. 
 > Non-Hodgkin’s lymphoma 
is one of the most com-
mon cancers in men and 
women. It accounts for 
about 4 percent of all can-
cer in the United States, 
according to the American 
Cancer Society. 
 > About 72,240 people in 
the United States will be 
told they have non-Hodg-
kin’s lymphoma in 2017, 
according to the American 
Cancer Society.
 > People with cancer who 
have difficulty eating or 
a loss of appetite during 
treatment should, accord-
ing to the National Cancer 
Institute, eat small and 
frequent meals, avoid 
foods low in calories and 
protein, try high-calorie, 
high-protein drinks when 
not hungry, eat foods at 
room temperature, and 
avoid spicy foods.
TWO TYPES OF LYMPHOMA
There are two forms of lymphoma: 
Hodgkin’s and non-Hodgkin’s. With 
Hodgkin’s lymphoma, cancer cells 
make up just a small number of the 
cells in a cancerous lymph node. In 
non-Hodgkin’s lymphoma, cancer 
cells make up most of a tumor. 
The George Washington University Cancer Center     9
Mitchell Smith: 
Paving the Way for 
Cutting‑Edge Clinical Trials
siTTing in his neW office on the eighth floor of the Science and 
Engineering Hall, Mitchell Smith, MD, PhD, associate center director 
for clinical investigations at the George Washington University (GW) 
Cancer Center, lays out his vision for a center that pioneers new treat-
ments, rapidly delivers them to patients, and continually engages 
with the community it serves.
“It’s always been the goal to take good care of patients, but now 
we want to be on the cutting edge in terms of research and provid-
ing access to new drugs for patients,” he says. “Ultimately, [we want 
to] take science that’s developed here, in the medical school and the 
laboratories … to our patients.”
In his role, Smith oversees all cancer clinical trials. He sees the GW 
Cancer Center becoming a hive of activity, opening new trials at a fast 
clip, while developing a strong focus on in-house science. 
Smith also works to enhance trust in the community in order to 
grow participation in the trials the center runs. It’s the GW Cancer 
Center’s job to reach out to people living in underserved commu-
nities, and educate those residents, he says. “We’ll talk to people 
who know the community, to learn how to reach residents and show 
them that the best treatment is often [provided in] a clinical trial,” 
Smith says.
For much of his career, Smith concentrated on blood cancers, such 
as leukemia and lymphoma. He comes to GW from Cleveland Clinic’s 
Taussig Cancer Institute, where he served as director of the lymphoid 
malignancy program. Prior to that, Smith held the role of director for 
the lymphoma program at Fox Chase Cancer Center in Philadelphia. 
Smith says coming to GW is an exciting opportunity, adding he 
couldn’t turn down the chance to build up the clinical investigations 
division of a new and evolving cancer center.
“You don’t always have a chance to get in on the ground floor with 
people you respect and trust,” he adds, noting that he knows GW 
Cancer Center Director Eduardo M. Sotomayor, MD, from his years in 
the lymphoma field. “This is a new challenge … I bring certain exper-
tise, but I have a lot of learning to do.”
REACHING OUT TO UNDERSERVED COMMUNITIES
Mitchell Smith, MD, PhD, is the associate center director for 
clinical investigations at the GW Cancer Center. In that role, 
Smith oversees all cancer clinical trials. He also works to 
enhance trust in the community in order to grow participa-
tion in the trials the center runs, making a concerted effort 
to reach out to people living in underserved communities.
BY KATHERINE DVORAK
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The Tagline for The naTional Cancer 
Institute (NCI) Cancer Centers Program 
— “The whole is greater than the sum of 
the parts” — couldn’t be more apt for the 
George Washington University (GW) Can-
cer Center as it seeks a prestigious NCI 
designation.
Pathway to NCI Designation
The goal, according to Michael Bene-
dict, PharmD, associate center director for 
administration and finance at the GW Can-
cer Center, is to bring together the best 
minds across departments, the university, 
and the research community to create a 
competitive, high-quality cancer center 
BY CAROLINE TRENT-GURBUZ
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worthy of the designation. Benedict and 
Eduardo M. Sotomayor, MD, director of 
the GW Cancer Center, have long been in 
the business of NCI designations — Bene-
dict on the planning and administration 
side, Sotomayor on the programming and 
reviewing side — and with their experience, 
they’ve crafted a five-year plan to reach 
that target. 
Building Blocks
The designation is “first and foremost a 
grant,” Benedict explains. “It’s something 
we have to apply for, and it’s very competi-
tive — there are a limited number of these 
types of centers in the country.”
Currently, there are just 69 NCI-des-
ignated cancer centers spread across 35 
states and the District of Columbia. Each 
one, Benedict adds, has a different model, 
though all are built on six essential charac-
teristics: a focus on cancer research, a dem-
onstration of institutional commitment, a 
center director with the appropriate quali-
fications and authorities, transdisciplinary 
collaborations, suitable physical space, and 
organizational capabilities that allow for 
and facilitate the advancement of science.
“We’re beginning to assemble the 
building blocks,” Benedict says, pointing 
to the six essential characteristics as the 
framework guiding his and Sotomayor’s 
plan. “We’re now going through and creat-
ing scientific themes that will roll into pro-
grams for the cancer center.”
Those themes, with additional sub-
projects, are designed to help the center 
“find [its] own niche,” Sotomayor says. “I 
think by doing that, we’re going to have 
a very good chance down the road to get 
NCI designation, so we need to be very 
strategic in our efforts.”
The first, a hot topic among research-
ers, is cancer immunology and immuno-
therapy, which involves the investigation 
of the immune system’s role in cancer de-
velopment and treatment.
The second, a microbiology oncology 
program (see page 14 for more details) 
that builds on the strengths of the SMHS 
Department of Microbiology, Immunol-
ogy, and Tropical Medicine, links campus 
scientists who are studying virus-initiated 
cancers, the influence of the microbiome, 
and the role of endogenous retroviruses.  
The third theme, cancer biology, is a 
basic science program that “looks at the 
genetics of cancer, how the control of 
cell growth goes awry,” Benedict says, 
while a fourth, which continues to evolve, 
examines cancer through the lens of en-
gineering. That particular prong also in-
corporates faculty from the School of En-
gineering and Applied Sciences into the 
fight against cancer, a key collaboration 
that highlights the GW Cancer Center’s 
overall aim of fostering a cross-disciplinary 
research community. 
“We’re also recruiting scientists to fill 
unique needs,” Benedict says, “and we’re 
linking laboratory scientists with clinical in-
vestigators so that we can translate scientif-
ic discoveries to our patients and have our 
patient experience inform the laboratory.”
Finally, the GW Cancer Center will focus 
on clinical and population-based research, 
“where our science interfaces with our pa-
tient care and the community we serve,” 
says Benedict. 
The Application Process
Once Benedict and Sotomayor have es-
tablished the scientific themes and the es-
sential characteristics, they will package 
those into an application and submit it to 
the NCI, most likely in 2021 or 2022. 
The post-submission process includes 
a peer-review system where nationally 
known scientific leaders evaluate the GW 
Cancer Center for the NCI. “If you have 
shown impact and you score high enough, 
you might receive the designation,” Bene-
dict says.
In addition to the coveted NCI designa-
tion, a successful submission will also earn 
the GW Cancer Center a $1 million grant to 
support further development of the cen-
ter’s infrastructure and shared resources. 
What’s key, Benedict says, is guidance 
and advice. The GW Cancer Center team, 
for instance, is using an external advisory 
board (EAB), made up of members from 
other cancer centers across the coun-
try. “The EAB helps keep us on track and 
makes sure we maintain the focus of creat-
ing an impact on [cancer],” says Sotomayor. 
“We’re recruiting 
scientists to fill 
unique needs, 
and we’re linking 
laboratory 
scientists 
with clinical 
investigators 
so that we can 
translate scientific 
discoveries to 
our patients.”
MICHAEL BENEDICT, PharmD
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“They will tell us when they think we are 
ready to make an application.”  
Likewise, Benedict and Sotomayor will 
meet with NCI members, who will weigh in 
on the best time to submit an application. 
Each NCI designation lasts for five years, 
and a different set of centers are under 
review three times per year. So, Benedict 
explains, timing can be critical; if the team 
is planning to submit during the same pe-
riod as older, larger, and more established 
centers, there could be fewer resources 
available, and there may be a recommen-
dation to wait for the next review. 
The Impact 
While the designation itself is prestigious, 
and $1 million is always useful, the benefits 
of an NCI cancer center extend far beyond 
the potential funding. 
“The designation will help draw patients, 
it gives our faculty increased reputations, 
it enables us to recruit better scientists,” 
Benedict says. “It really changes the cul-
ture of what we’ve got here.” 
The designation also drives economic 
development. As scientists, recruited to 
join the center, move to the District, they 
bring with them teams of people, who sub-
sequently invest in the area. 
Most importantly, however, the NCI 
designation — and the research that comes 
with it — translates to better patient care. 
“We take care of patients differently and 
better in NCI cancer centers than else-
where,” Benedict says. “It’s the same con-
cept that transcends the laboratory side to 
the patient care side, where we’re organiz-
ing people around the diseases and pa-
tients. The care is different and enhanced.” 
NCI Designated Cancer Centers
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Comprehensive Centers meet NCI standards in six essential characteristics:
 > focus on cancer research
 > demonstration of institutional commitment
 > qualified center director
 > transdisciplinary collaborations
 > suitable physical space
 > organizational capabilities to facilitate the advancement of science
69
NCI-DESIGNATED CANCER CENTERS
47 Comprehensive Cancer Centers
15 Cancer Centers
7 Basic Laboratory  Centers
4%
Just 4 percent of the roughly 1,500 
cancer centers in the United States 
are recognized as Comprehensive 
Cancer Centers, Cancer Centers, 
or Basic Laboratory Centers
*Data from the National 
Cancer Institute website, nci.org 
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A Policy of Improving Access to Care
The george WashingTon UniversiTy (gW) Cancer Center is a bit like a toddler who 
is ready to run soon after mastering the walk. Less than two years after its founding, GW 
Cancer Center is reshaping the care landscape in Washington, D.C. One of its most signif-
icant achievements to date is radical improvement in access to cancer care for Medicaid 
beneficiaries who, officials say, have had to cope with delayed and fragmented service 
care across a variety of health care providers and systems. 
The initiative was led by Associate Center Director Mandi Pratt-Chapman, MA, the 
dynamo behind patient-centered initiatives and health equity at the GW Cancer Center. 
“Dr. Sotomayor [director of the GW Cancer Center] wants us to have a policy presence 
given our unique location in the nation’s capital,” she explains. “We have resources to put 
together a larger policy portfolio, but for now the focus is on the Medicaid project.”
Pratt-Chapman has held a series leadership positions in the cancer community and 
was the driving force behind GW’s rise to national prominence in survivorship and pa-
tient-centered initiatives. Even before she arrived at GW, Pratt-Chapman was aware of 
access to care issues in the District of Columbia, and says she’d been hearing “that there 
were few oncologists who would take Medicaid patients.” This was all very confusing from 
the patient’s perspective. “It should not be for the patient to have to shop around and 
piece together the care they need,” she says. “If you have a cancer diagnosis it should be 
easier to access the care you need.”
Pratt-Chapman works with the assistance of Claudia Schlosberg, Medicaid director at 
the D.C. Department of Health Care Finance, bringing stakeholders together as part of 
a policy, systems, and environmental (PSE) change effort to improve access to the con-
tinuum of cancer care services for Medicaid beneficiaries.
GW Cancer Center discovered that the reason providers were not participating in the 
Medicaid network was that chemotherapy reimbursement was largely compensated by 
Medicaid below the drug acquisition cost. A push was made to adjust drug reimburse-
ment to match Medicare reimbursement. “Sharing data and information, and having 
frank discussions led to policy changes to address these access barriers,” says Schlos-
berg. “There’s been a significant improvement of Medicaid operations.”
Aiding in the effort was Sara Rosenbaum, JD, the Harold and Jane Hirsh Professor 
of Health Law and Policy at the Milken Institute School of Public Health at GW. “I pro-
vided additional information to Mandi about the D.C. program and also participated in 
the meetings with Claudia,” says Rosenbaum, adding that she shared the view that the 
program as structured did not do enough to make medical oncology services accessible. 
“Now, drugs are available in more medical oncology locations and more doctors are see-
ing more medical oncology patients covered by Medicaid,” she explains. 
Asked why this disparity in access remained unresolved for so long, Schlosberg said 
that since she became Medicaid director in 2014, “my priorities have been to advance the 
creation of enduring systems to ensure the Medicaid program operates efficiently, effec-
tively, and in the best interest of District residents. This means identifying, and, wherever 
possible, eliminating barriers to access and improving quality.”
Rosenbaum says that other policy initiatives are being considered. “Mandi and I have 
talked about other things that could be done — such as better survivorship programs, 
better outreach programs,” says Rosenbaum. Pratt-Chapman notes that there is huge 
potential “in having some of the nation’s best policy experts at GW.” 
BY STEVE GOLDSTEIN
“It should not be 
for the patient 
to have to shop 
around and piece 
together the care 
they need.”
MANDI PRATT-CHAPMAN, MA
PATIENT-CENTERED INITIATIVES 
Mandi Pratt-Chapman, MA, as-
sociate center director of the GW 
Cancer Center, is the force behind 
the center’s patient-centered 
initiatives and health equity.
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A CONFLUENCE 
OF SCIENCE
BY CAROLINE TRENT-GURBUZ
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iT Was easy To PUT it together, recalls 
Eduardo M. Sotomayor, MD, director 
of the George Washington University 
(GW) Cancer Center. 
“All the ingredients are here. Our job 
was to put them together to prepare a 
nice meal,” he says. “I’m confident be-
cause we have good science, so we’ll 
be able to move the field forward.”
The meal is microbial oncology, and 
with each course of the meal comes an 
expert chef, starting with Douglas Nix-
on, MD, PhD, chair of the Department of 
Microbiology, Immunology, and Tropi-
cal Medicine and Walter G. Ross Pro-
fessor of Basic Science Research at GW 
School of Medicine and Health Sciences 
(SMHS), and newcomer Kieron Dun-
leavy, MD, who joined the team in April 
from the National Cancer Institute (NCI).
As Sotomayor explains, microbial 
oncology — or the study of how mi-
crobes, such as viruses, bacteria, or 
parasites, can be manipulated to fight 
cancer — boils down to the immune sys-
tem. “These days, we have the technol-
ogy to modify immune cells or microbes to fight cancer,” Sotomayor says. 
One modified immune cell, known as a chimeric antigen receptor (CAR) 
T-cell, is particularly effective against lymphomas and some types of leuke-
mia. “These days, we have also learned that what we call ‘inflamed’ cancers 
are the ones more likely to respond to novel immunotherapeutic approach-
es,” he adds. In these kinds of cancer, the body has an inflammatory reac-
tion, and the immune cells are subsequently more receptive to treatment. 
Non-inflamed cancers, or those with an absence of inflammation, are harder 
to treat. That’s where microbes come in.
AN INTERDISCIPLINARY APPROACH 
Douglas Nixon, MD, PhD, chair of 
the Department of Microbiology, 
Immunology, and Tropical Medicine 
and Walter G. Ross Professor of Basic 
Science Research at SMHS, is examin-
ing the impact of human endogenous 
retroviruses on certain types of cancers 
with a $2.2 million NCI grant.
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Microbes have the unique ability to travel to hard-to-reach areas of the 
body, such as the pancreas, gallbladder, or prostate, that tend to exhibit 
“non-inflamed” features. Some microbes are also multicellular organisms 
that have circulatory and secretory systems, and they can be modified 
to produce biological agents to potentially fight cancer. Additionally, re-
searchers can use anti-microbial therapies that can easily kill the “therapeu-
tic microbes,” Sotomayor says, to prevent harming the host.
“By using these microbes … we [might be able to] convert non-inflamma-
tory tumors into more inflammatory ones,” Sotomayor explains, adding that 
it makes treatment easier and more effective.
Using genetically modified, or transgenic, parasites to both convert tu-
mors and deliver cancer therapy is an important goal of the microbial on-
cology program, but researchers have other significant goals as well. The 
program also prioritizes the influence of intestinal or 
skin microbiota on cancer development and therapy — a 
rapidly evolving field that links microbial composition in 
compartments such as the gastrointestinal (GI) tract with 
the development of GI malignancies. Rounding out the 
innovative program is the study of retrovirus-related ma-
lignancies and the broader role of human endogenous 
retroviruses (HERVs) in immuno-oncology. That’s the area 
in which Nixon’s talent lies.
With a $2.2 million NCI grant, Nixon, alongside GW 
collaborators, is examining how HERVs impact certain 
types of cancers. HERVs, he explains, are ancestral rem-
nants of past viruses, which infected ancient humans, 
non-human primates, and other species, becoming inte-
grated into DNA. These ancient viruses have remained 
in modern human DNA, passing from mother to child. 
Nixon’s research team has long published studies on the 
effect of HIV infection on HERVs, and has found there may 
also be a link between HIV and cancer. 
“It appears that breast and prostate cancer are found 
less frequently in HIV-infected people than in the gen-
eral population,” Nixon says. “That is a puzzle, because 
we think of HIV infection as being associated with people 
having more cancer. That is true for cancers such as anal 
cancer, but it seems strange to have a virus infection like 
HIV, which appears to, in some senses, protect against 
prostate or breast cancer.”
BIOLOGICAL AGENTS FIGHTING CANCER
Microbial oncology is the study of how 
microbes, such as viruses, bacteria, or 
parasites, can be manipulated to fight cancer. 
Microbes have the unique ability to travel 
to hard-to-reach areas of the body, such as 
the pancreas, gallbladder, or prostate. Some 
microbes are also multicellular organisms 
that have circulatory and secretory systems, 
and they can be modified to produce 
biological agents to potentially fight cancer.
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Nixon had already discovered that HIV wakes up some 
of the transcriptionally silent HERVs; therefore, it might 
be possible that in patients with HIV, the newly activat-
ed HERVs stimulate an immune response, which surveils 
prostate and breast cancer cells that could be expressing 
the same HERVs. To test this hypothesis, Nixon, in collabo-
ration with Matthew Bendall, a PhD rotation student, and 
Keith Crandall, PhD, director of the GW Computational 
Biology Institute at the Milken Institute School of Public 
Health at GW, developed “Telescope,” a computational 
pathway program designed to determine which HERVs 
are expressed in prostate, breast, and colon cancers, in 
patients with and without HIV. 
“This is really a brand-new tool, which we think will be 
incredibly valuable in looking for expression of these en-
dogenous retroviruses in a number of different disease 
categories, including in cancer,” Nixon says.
Like Nixon, Dunleavy is building his microbial oncol-
ogy research on past experience in HIV. “I’ve got a back-
ground in developing treatments for HIV-associated 
lymphomas, and we thought at GW it would be very inter-
esting to have a microbial oncology program where we 
not only look at HIV, but also look at … other organisms 
and viruses that may contribute to lymphomas,” he says. 
As the field progresses, Dunleavy explains, researchers are developing 
a better appreciation of the role viruses can play in cancer. Sotomayor is 
building the mission of the GW Cancer Center around that development.
“The lessons we are learning from immunology and infectious disease 
are driving the knowledge that we are uncovering in cancer immunology,” 
he says. “As we learn how the immune system fights infection, at the mo-
lecular level, all the lessons we learn from that can be applied to harnessing 
the immune system to fight cancer.”
Right now, Sotomayor, with team members such as Nixon and Dunleavy, 
is building the GW Cancer Center’s clinical research infrastructure, but his 
ambitions — he’d like to see ideas translated to the clinic within five years 
— hinge on his instincts about cancer. “There is a confluence of [using] im-
munology against infectious diseases and immunology against cancer, and 
I think in the future, we’re going to see there is a closer link between these 
two fields than we thought,” he says. “That’s the reason that bringing to-
gether these experts makes a lot of sense.”
With a $2.2 million NCI grant, 
Nixon, alongside GW collaborators, 
is examining how human 
endogenous retroviruses impact 
certain types of cancers. 
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COMPLEMENTS 
TO CARE
The George Washington University Cancer Center     19
BreasT cancer is one of the leading forms of cancer facing the country, with more than 
250,000 new cases diagnosed each year, according to the Centers for Disease Control. Although 
the incidence of breast cancer has dropped annually since 2000, Washington, D.C., still has one 
of the highest rates in the country. To combat this ongoing problem, the George Washington 
University (GW) Comprehensive Breast Center (Breast Care Center), supported by clinical part-
ners the GW Medical Faculty Associates, GW Hospital, and the GW Cancer Center, has grown 
to become one of the area’s leading breast cancer programs. GW’s nationally accredited center 
offers multidisciplinary services for early detection, diagnosis, and treatment of breast cancer us-
ing advanced technologies to help breast cancer patients navigate their way through diagnosis, 
treatment, and survivorship.
For nearly a decade, the Breast Care Center has bolstered its gold-standard clinical care by 
offering a one-time complementary medicine clinic each month. The clinic serves as a sampler 
for many of the integrative care options available such as physical therapy (PT), therapeutic mas-
sage, Reiki, acupuncture, and naturopathic consultation.
“[The clinics] allow us to provide a more holistic approach to patient care,” says Christine Teal, 
MD, chief of the Division of Breast Care, associate professor of surgery at GW School of Medicine 
and Health Sciences, and director of GW’s Breast Care Center. 
Treatments for breast cancer can take a toll on patients. Side 
effects such as pain, fatigue, or depression are common, but 
often slip past conventional medical therapies. Complemen-
tary medicine can sometimes offer patients relief where tradi-
tional medicine leaves off. 
For patients, such as Shaunique Pierre, the free clinic offers 
a welcome opportunity to sample some of the holistic offer-
ings available and address some of the lingering side effects 
of treatment.
“My arms weren’t going over my head without some dis-
comfort, and I had lost sensation in my upper arm,” explains 
Pierre, who was having mobility issues in her shoulder area 
following reconstructive surgery. “The PTs do an amazing job, 
they handle everything. Now the sensation is starting to come back.” 
It’s nice, says Teal, “when we are doing this complementary clinic, for patients to be seen by a 
PT as well,” adding that, while physical therapy is covered under most insurance plans and Breast 
Care Center patients use the PT services through the hospital, the extra session is well received.
Teal attributes her interest in complementary medicine to a moment early in her career when 
her best friend was diagnosed with breast cancer. During treatment, Teal’s friend explored com-
plementary medical treatments that were far more common and 
accepted in her Colorado home. Her experience sparked Teal’s 
curiosity. 
“I just loved the holistic approach,” she recalls. “Herbs that 
helped during chemotherapy, things that helped reduce neurop-
athy, it was a unique emphasis on well-being and how to make 
yourself feel better while going through a more conventional 
treatment plan. I hoped that someday I could provide those kinds 
of services to my patients.
“I think most physicians these days are open to complementary 
medicine practices,” Teal adds, stressing that these services are 
called complementary medicine for a reason; they aren’t alterna-
tives to conventional treatment protocols. “It’s always in addition 
to standard treatment. [Complementary medicine] is just trying to 
find a way to get patients through standard treatment feeling a 
little bit better.”
BY THOMAS KOHOUT   |   PHOTOGRAPHS BY SUSAN GENDRON 
THE HEALING TOUCH
Reiki is a traditional Jap-
anese technique using 
specific hand positions 
on or near a patient’s 
body. Through gentle 
yet methodical healing 
touch, the Reiki therapist 
can direct energy into the 
patient to activate the 
natural healing processes 
of the patient’s body 
and restore physical and 
emotional well-being.
ABOUT THE PHOTOGRAPHER
Susan Gendron is an award-win-
ning photographer and gradu-
ate of the University of New 
Hampshire with a BA in studio 
art with a concentration in pho-
tography. She is self-taught in 
digital shooting, darkroom, and 
archival printing techniques. 
She is also a breast cancer 
survivor and credits her good 
health to the care she received 
from the physicians, nurses, and 
staff of the George Washington 
University (GW) Medical Faculty 
Associates and the GW Hospital.
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FINDING THE RIGHT DIET
Naturopathic consultation 
enables patients to discuss 
nutritional approaches to  
their cancer treatments, such 
as special diets and nutri-
tional supplements. These 
therapies range from follow-
ing a basic, healthy vegeta-
ble-based diet to adopting 
highly restrictive diets and 
supplement regimens. 
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ACUPUNCTURE FOR 
GREATER WELL-BEING
Acupuncture is a centuries-old 
Chinese medicine that uses 
hair-like needles to stimulate 
key points along the nervous 
system. Proponents believe 
this stimulation sparks a bio-
chemical response that can be 
used to treat nausea or pain 
and promote greater physical 
and emotional well-being.
STRENGHTEN-
ING THE BODY
Physical approaches, 
such as exercise, progres-
sive deep relaxation, 
massage, chiropractic 
or osteopathic thera-
pies, among others, 
are designed to relax, 
align, energize, and 
strengthen the body. 
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A Poodle 
Among 
Patients
“He loves people, and he’s calm. 
He’s the perfect therapy dog.”
AMY KAPLAN
BY CAROLINE TRENT-GURBUZ
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every Wednesday, James The Poodle — occasionally sporting thematic wear, be it a 
cowboy hat, colorful bandana, or pumpkin costume — and his owner, Sandra Johnson, vis-
it the Infusion Center at the George Washington University (GW) Cancer Center. James’ 
presence is met with pats and rhetorical queries of “who’s a good boy?” by patients and 
staff members alike.
On this particular Wednesday, James is warmly greeted by Jennifer Bires, LICSW, a 
former clinical social worker at the GW Cancer Center, before he clicks through the door 
to the patients receiving doses of chemotherapy.
The pet therapy program, Bires says, was started by Jamie Glidewell, a social work 
intern at the GW Medical Faculty Associates, a year ago. “She worked in hospice before 
she came here and started a pet therapy program there. 
She saw how beneficial it was,” Bires explains. “[All of the 
patients] look forward to seeing James. It’s a really great 
break in their long time being here; it’s a reprieve from 
what’s going on.”
For patient Amy Kaplan, who has her own dog, 13-year-
old Lulu, seeing James “is a highlight, that’s for sure.” 
“He loves people, and he’s calm,” she says, reaching 
down from her reclined chair to rub James’ back. “He’s the 
perfect therapy dog.”
James is newly certified, not quite a year into his new 
role. The idea to transition the almost 7-year-old poodle 
from pet to therapy dog sparked after Johnson, a native 
of Orlando, Florida, read coverage of the June 2016 night-
club shooting in her hometown. 
“This group was sending therapy dogs to Florida to 
help with the grieving of all those families, and something 
about the article caught my attention,” she recalls. “I de-
cided to look up the therapy dog group [Therapy Dogs 
International]. I thought, ‘You know what, this is perfect 
timing; this is meant to be. I’m going to sign him up and 
get registered.’”
After a temperament evaluation, James was regis-
tered, and Johnson scouted out potential clinics. The GW 
Cancer Center was the first place she called, and the re-
sponse was immediate. “We set it up to start coming every 
Wednesday,” she says. “James really likes it.”
Although he isn’t the only therapy dog who visits pa-
tients at the GW Cancer Center, James is the most regular 
one. “There are days you can tell people are really hap-
py to see him,” Johnson says. “He’s not a big kisser; he 
doesn’t really give out a lot of them. But sometimes he’s really kissing somebody and 
giving them lots of love, and you can tell that he’s really helped some people, taken their 
mind off things.”
Patient Taylor Ferrell agrees that James always makes him feel better. “You could bring 
him every day. That would make me happy.”
PUPPY LOVE
GW’s pet therapy program was 
started a year ago by Jamie Glide-
well, a former social work intern 
at the GW Medical Faculty Associ-
ates. Of the therapy dogs who visit 
patients at the GW Cancer Center, 
James the Poodle, pictured 
here, is the most regular one. 
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The George Washington University Cancer Center with support provided by the Dr. Cyrus and Myrtle 
Katzen Cancer Research Center (Katzen Center) supports a wide variety of holistic and wellness services 
for cancer patients and their families. These groups are free of charge and open to the community.
SUPPORT GROUPS
THE GW MEDICAL  
FACULTY ASSOCIATES 
(GW MFA)
2150 Pennsylvania Ave., N.W.
Washington, D.C. 20037
ACTIVE TREATMENT
(all cancers)
Open to patients currently in treatment. 
Registration required.
Second and Fourth Wednesday
each month, 12:30–1:30 pm
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
ADVANCED BREAST
CANCER GROUP
Open to patients with stage IV  
breast cancer. Registration required.
Fourth Tuesday of each month,
Noon–1 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
BRAIN TUMOR SUPPORT GROUP
Open to brain tumor survivors/patients 
and caregivers.
Registration required.
First Tuesday of each month,
6–7:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
CAREGIVERS’ SUPPORT GROUP
Open to caregivers of those diagnosed 
with cancer to share common concerns, 
give and receive advice, and learn 
coping skills. Registration required.
Third Tuesday each month, 
12:30–1:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
GENTLE YOGA
This group introduces patients 
and caregivers to the physical and 
emotional benefits of yoga.
Tuesdays, 4–5 p.m.
GW Marvin Center,
Fifth floor activities room
800 21st St., N.W.
Facilitator: Yael Flusberg
eruiz@mfa.gwu.edu
202-677-6228
HEAD AND NECK CANCER GROUP
For patients, survivors, and caregivers 
of head and neck cancers. Registration 
required.
First Tuesday each month,  
12:30–1:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
KIDS’ CLUB
For families with kids (ages 6–12)
in which a parent or sibling is in 
treatment or is a survivor.
Fourth Wednesday each month,
6–7:30 p.m.
Smith Center for Healing and the Arts
1632 U St., N.W.
Facilitators: Erin Price and  
Lauren Broschak
202-483-8600
MULTIPLE MYELOMA GROUP
This group is open to multiple myeloma 
patients/survivors and caregivers. 
Registration required.
Third Tuesday each month,
5:30–6:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
NUTRITION CLUB
First Monday each month,
Noon–1 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Jennifer Leon
202-741-6489
PROSTATE CANCER
EDUCATIONAL GROUP
The prostate cancer educational group 
is free and open to patients and 
survivors in the Washington, D.C., area. 
Registration required.
Second Tuesday each month,
6–7 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak
lbroschak@mfa.gwu.edu
202-677-6229
SURVIVORSHIP SERIES
An educational series featuring a 
different speaker each month.
Second Thursday each month,
11:45 a.m.–12:45 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak
lbroschak@mfa.gwu.edu
202-677-6229
YOUNG ADULT GROUP
Young adults (19 to 39 years of age) 
who are currently in treatment or are 
cancer survivors.
Third Sunday of each month,
5–6:30 p.m.
Smith Center for Healing and the Arts
1632 U St, NW
Facilitator: Jennifer Bires
202-483-8600
Parking is validated for all groups 
at the GW Cancer Center. For 
more information about upcoming 
support groups and events, visit
smhs.gwu.edu/katzencancer/events.
Executive 
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Jeffrey S. Akman, MD ’81, RESD 
’85, Vice President for Health 
Affairs, Walter A. Bloedorn Professor 
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dean, the George Washington 
University (GW) School of 
Medicine and Health Sciences
Kimberly Russo, MBA, 
MS, CEO and managing 
director of GW Hospital
Robert E. Kelly, MD, CEO of 
the clinical enterprise, GW 
Medical Faculty Associates
External 
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Edward Benz, MD, former 
director, Dana Farber Cancer 
Institute / Harvard University
William Dalton, MD, PhD, former 
director, H. Lee Moffitt Cancer Center
Stan Gerson, MD, director, Case 
Comprehensive Cancer Center / 
Case Western Reserve University
Stephen B. Gruber, MD, PhD, 
MPH, director of the University 
of Southern California Norris 
Comprehensive Cancer Center
Helen Heslop, MD, PhD, 
director, Center for Cell and Gene 
Therapy, Baylor University
Robert DiPaola, MD, dean, 
University of Kentucky 
College of Medicine
Marcy Waldinger, MS, former 
chief administrative officer, 
University of Michigan
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Solutions for the Skin
cancer TreaTmenTs indUce a hosT 
of side effects, but among the most 
distressing can be dermatological: 
hair loss, extremely dry skin and rash-
es, infections, painful nail conditions. 
Some patients turn away from treat-
ment altogether, while others simply 
battle through. Adam Friedman, MD, 
associate professor of dermatology 
at the George Washington University 
(GW) School of Medicine and Health 
Sciences, however, believes he has a 
potential solution.
A new Supportive Oncodermatol-
ogy Clinic, falling under the umbrella of 
the GW Cancer Center and within the 
oncodermatology program, is de-
signed as a one-stop shop for patients. 
The clinic, which currently operates on 
a monthly basis, serves as a resource 
for both oncologists and their patients, 
while prioritizing survivorship and in-
creasing knowledge of the burgeoning 
supportive oncodermatology field.
“This is somewhat unique … there 
are only a handful of other institutions 
across the country that offer a clinic 
that addresses the well-established 
and, for the most part, expected side 
effects to many if not all of the cancer 
therapies that are life-saving but also 
come with some significant baggage,” 
Friedman says.
The side effects, he adds, can 
range from chemotherapy-induced 
alopecia, or hair loss, to xerosis, se-
verely dry skin that can cause fissures 
in the hands and feet that are “exqui-
sitely painful and hard to heal.” 
What’s critical is seeing patients in 
the clinic early, when they can receive 
preventive medication to possibly 
limit side effects, as well as during 
and after cancer treatment. “A lot of 
the skin, hair, and nail side effects 
we see can often persist well beyond 
the time when treatment has ended,” 
Friedman explains. “Plus, having a his-
tory of any type of cancer increases 
your risk for skin cancer. So these 
patients need a different level of sur-
veillance, a different level of care than 
someone who has not undergone 
treatment for cancer.”
In addition to monitoring patients’ 
progress, Friedman also catalogues 
any new side effects and potential 
treatments. Patients in treatment at the 
GW Cancer Center, he adds, may have 
their oncologist or nurse contact the 
oncodermatology scheduling appoint-
ment team to set up a visit to the clinic, 
while those receiving treatment outside 
of GW may contact the Department of 
Dermatology and request to be seen 
by an oncodermatologist. 
The side effects of cancer treatments can range from chemotherapy-induced alopecia, 
or hair loss, to xerosis, severely dry skin that can cause fissures in the hands and feet. 
SUPPORTIVE 
ONCODERMATOLOGY
The Supportive Oncodermatology 
Clinic, launched in part thanks 
to support from La Roche-Posay, 
will support cancer patients and 
survivors who suffer from the 
persistent side effects of cancer 
treatments, as well as provide 
diligent skin cancer surveillance. 
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